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Purpose: To analyze all nonlymphatic metastatic components (T4
and M1) of the current TNM system of lung cancer, with the
objective of providing suggestions for the next edition of the TNM
classification for lung cancer.
Material and Methods: Data on 100,809 patients were submitted to
the International Association for the Study of Lung Cancer Interna-
tional Database. Of these, 5592 selected T4M0 and M1 patients
fulfilled the inclusion criteria for the analysis. Specific categories of
clinically staged T4 (lesions not continuous with the primary tumor)
and M1 cases were compared with respect to overall survival using
Kaplan–Meier survival estimates and comparisons via Cox regression
analysis. Relevant findings were validated internally by geographic area
and type of database and were validated externally by the North
American Surveillance, Epidemiology and End Results Registries.
Results: Median survival for cT4M0 with malignant pleural effu-
sion was significantly worse than that of other cT4M0 patients (8
months versus 13 months) and was more comparable with M1 cases
with metastases to the contralateral lung only (10 months). M1 cases
with metastases outside the lung/pleura had a significantly poorer
prognosis than those with metastases confined to the lung, with a
median survival of 6 months.
Conclusions: Revisions to the TNM classification system for lung
cancer should include grouping cases with malignant pleural effu-
sions and cases with nodules in the contralateral lung in the M1a
category, and cases with distant metastases should be designated
M1b. In addition, cases with nodule(s) in the ipsilateral lung (non-
primary lobe), currently staged M1, should be reclassified as T4M0,
in accordance with the recommendations of the T descriptor sub-
committee of the IASLC international staging committee.
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(J Thorac Oncol. 2007;2: 686–693)
With changes in diagnostic capabilities, staging proce-dures, and treatment options, the TNM staging system
for lung cancer1 needs to be reexamined to optimize manage-
ment and outcomes. With the current system, patients within
the same stage group may have different prognoses; thus,
clinicians have problems initiating the appropriate treatment.
It has become clear that an international database to
inform future revisions of the TNM classification of lung cancer
would be of tremendous benefit. Thus, the International Staging
Project on Lung Cancer of the International Association for the
Study of Lung Cancer (IASLC) was initiated.2 The IASLC is
uniquely positioned to take on this project because it is the only
global organization dedicated to the study of lung cancer, with
membership including representatives from all disciplines in-
volved in lung cancer care. This staging project was approved by
the board of the IASLC in 1998,3 and by the end of 2005, data
from 100,809 patients treated for primary lung cancer around the
world from 1990 to 2000 had been submitted for review.
Detailed analyses of these data related to metastatic
disease (M1) have been performed to determine whether a
more uniform classification scheme based on outcome could
be achieved. This analysis included all patients with a solitary
metastasis. This included nodule(s) within the same lobe as
the primary tumor (currently classified as T4), the pleura
(currently classified as T4), nodule(s) within the same lung as
the primary tumor (currently classified as M1), and nodule(s)
in the other lung or extrathoracic sites of disease (currently all
classified as M1). After analysis, the cases with nodule(s) in
the same lobe or same lung will be discussed in a separate
manuscript focusing on subclassifications of T.4 Neverthe-
less, other cases initially classified as T4 on the basis of
extension into the pleural cavity will be discussed here.
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MATERIALS AND METHODS
Study Population
A total of 100,809 lung cancer cases were submitted to
the database. Of these, 81,021 cases had a new diagnosis of
either SCLC or NSCLC, adequate follow-up for survival, and
either a cTNM or pTNM designation at baseline. Of these
cases, 67,731 had NSCLC, including 53,646 clinically staged
cases and 33,933 pathologically staged cases. Twenty thou-
sand six patients had both a clinical and pathological stage
recorded. For the analyses concerning M stage, 5592 clini-
cally staged cases in categories T4 and M1 were selected. An
additional 1004 cases were included in secondary analyses of
best stage, where best stage is defined as the pathological
stage if available, and clinical otherwise. Table 1 shows the
distribution of stage information and treatment modalities for
all cases included in M category analyses.
The 6596 cases originated from four global regions:
Europe with 52% of cases, North America with 34%, Asia
with 11%, and Australia with 3%. For the 5592 cases in the
analysis of cases requiring a clinical stage (the primary
focus), the Asian contribution, composed entirely of surgical
cases, was reduced relative to the others (4%). Types of
contributing databases included clinical trial groups, regis-
tries, and surgical series (Table 2). A complete listing of data
contributors has been given in a previous paper.5
In accordance with recommended changes to the T
category,4 for this analysis the T4 group included cases with
additional nodule(s) in an ipsilateral lobe (formerly staged as
M1) and excluded cases that were staged T4 by virtue of
additional nodule(s) in the same lobe as the primary tumor.
These additional nodule(s) in the same lobe are now proposed
to be included in T3. For T4 cases, at least one T4 descriptor
had to be documented to be included in this analysis; likewise,
metastatic site was required forM1 cases. Unless we had explicit
information to the contrary, nodule(s) reported in the contralat-
eral lung that had the same histology and timing as the primary
were assumed to be metastases (provided the cases were staged
M1). Any nodules proven to have a different histology were
considered synchronous primaries, in which cases we included
only the highest-staged primary. Additional nodule(s) in a sep-
arate ipsilateral lobe were similarly treated, although the vast
majority of these cases were from the surgical databases.
Validation Analyses
Internal validation
Internal validation was performed by comparing the re-
sults of interest between types of databases (consortium/surgical
series versus clinical trials versus series/registries) and among
geographic regions (North America versus Asia/Australia versus
Europe). If the effects were relatively consistent within these
subgroups, the results were considered validated.
External validation
For external validation of T4 and M1, cases of non-
small cell lung cancer with similar features were selected
from the Surveillance, Epidemiology and End Results Reg-
istries database. The analysis used only those cases drawn
from 1998 to 2000, because changes to the classification of
certain characteristics (enacted in 1998) enabled the creation
of categories that matched those under the current study.6
Statistical Analysis
Survival was measured from the date of entry (date of
diagnosis for registries, date of registration for protocols) and
was estimated by the Kaplan–Meier method. Prognostic
groups were formally compared by unadjusted Cox regres-
sion analysis, with individual disease categories represented
by indicator variables. The SAS System for Windows version
9.0 was used for all analyses.
TABLE 1. Treatment Modality (Surgical versus Not) and Type of Stage Data Provided (Clinical
versus Path) for 6596 Cases Included in Analyses
Modality
Category Type of Stage Data Nonsurgical Surgical Total
T4 M0, any Na Clinical 255 60 315
Pathological 0 590 590
Both 0 201 201
Pleural dissemination Clinical 478 6 484
Pathological 0 260 260
Both 0 27 27
Contralateral lung nodules Clinical 362 0 362
Pathological 0 7 7
M1 distant Clinical 4285 31 4316
Pathological 0 4 4
Both 0 30 30
Total 5380 1216 6596
A subset of these cases (any with clinical stage available) formed the group for primary analyses of clinical stage.
a This category (1) includes same-side nodules (International Union Against Cancer 6 stage M1 but recommended change to T4 in
a separate paper4), and (2) excludes same-lobe nodules (International Union Against Cancer 6 stage T4 but recommended change to T3
in a separate paper4).
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RESULTS
Overall survival results for four subsets of T4 and M1
patients are shown in Figure 1 (clinical stage) and Figure 2
(best stage). They are summarized in Tables 3 and 4.
Malignant Pleural Effusion
Patients with a clinical finding of pleural dissemina-
tion (malignant pleural effusion or pleural nodules) and
without other metastatic disease (n  488) had a median
overall survival of 8 months versus 13 months for other
cT4 M0 (any N) patients (p  0.0001), and the difference
persisted over time. The 1- and 5-year survival rates for the
pleural dissemination group were 36% and 2% versus 53%
and 15% for the remaining cT4. Those with pleural me-
tastases according to best stage had a median survival of
10 months versus 13 months for other T4 cases by best
stage.
Additional Nodule(s) in the Contralateral Lung
Additional nodule(s) detected in the contralateral lung
by imaging studies precludes surgery; therefore, results for
this M1 subgroup are driven primarily by clinical stage.
Median overall survival for this group was 10 months, with a
1-year survival rate of 45% and a 5-year survival rate of 3%.
It was not possible to differentiate between single and mul-
tiple lesions in the contralateral lung. Although there was a
statistically significant difference in survival on clinical stag-
ing between the pleural dissemination group versus the con-
tralateral nodule(s) group (p  0.0235, in favor of the
contralateral nodule(s) group), the two groups are closer to
each other in prognosis than they are to the proposed (new)
T4, and they both differ significantly from the subset of M1
that have distant metastases (p  0.0001 for both compari-
sons). Furthermore, in an analysis of best-stage categories,
the group with additional nodules in the contralateral lung
differs significantly from the group with nodule(s) in the
ipsilateral lung in a different lobe than the primary (p 
0.0001) (Table 5).
Extrathoracic Metastases
As a group, patients with distant metastases had a
poorer prognosis, with a 6-month median survival and 22%
surviving at 1 year. Reported sites of extrathoracic metastases
at presentation were as follows: multiple sites (43%), bone
(24%), liver (10%), brain (9%), adrenal (6%), skin (1%),
and other single sites (7%). The median survival of patients
with multiple distant metastatic sites was 5 months, which
was slightly worse than the 6-month median for patients with
TABLE 2. Summary of Data Source Types for 6596 Cases Included in Analyses
Group Type
Category Clinical Trial Consortium/Surgical Series Registry/Series Total
T4 M0, any Na 148 782 176 1106
Pleural dissemination 253 330 188 771
Contralateral lung nodules 313 7 49 369
M1 distant 2012 742 1596 4350
Total 2726 1861 2009 6596
a This category (1) includes same-side nodules (International Union Against Cancer 6 stage M1 but recommended change to T4 in a separate
paper4), and (2) excludes same-lobe nodules (International Union Against Cancer 6 stage T4 but recommended change to T3 in a separate paper4).
FIGURE 1. Overall survival comparisons for proposed clini-
cal stage T4 (any N) N0 versus proposed categories M1a
(pleural dissemination) and M1a (contralateral lung nodules)
versus M1b (distant metastases). The T4 group includes
cases with same-side nodules, in accordance with the pro-
posal to move these cases to the T4. The T4 group excludes
the cases with same-lobe nodules, in accordance with the
proposal to move this group to the T3.
FIGURE 2. Overall survival comparisons for proposed best
stage T4 (any N) versus proposed categories M1a (pleural
dissemination) and M1a (contralateral lung nodules) versus
M1b (distant metastases). The T4 group includes cases with
same-side nodules, in accordance with the proposal to move
these cases to the T4. The T4 group excludes the cases with
same-lobe nodules, in accordance with the proposal to
move this group to the T3.
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a reported single distant metastatic site (p  0.006). The
1-year survival rates for these two groups were 20% and
23%, respectively.
Patient survival with metastases to single sites of
interest (with the brain as a primary focus) was not
different and resulted in a 6-month median survival, with
the exception of brain, which had a 5-month median. There
was essentially no difference between single-site locations.
Although a therapeutic decision to operate on single syn-
chronous brain metastases in patients with otherwise re-
sectable tumors is frequently necessary, it was impossible
within the available cases in the database to evaluate
possible prognostic differences between single and multi-
ple brain metastases. In fact, it was not possible to analyze
single versus multiple sites in any extrathoracic organ.9–11
Recommendations
Y Reclassify pleural dissemination (malignant pleu-
ral effusions, pleural nodules) from T4 to M1a.
Y Subclassify M1 by additional nodules in the con-
tralateral lung as M1a.
Y Subclassify M1 by distant metastases (outside the
lung/pleura) as M1b.
Internal Validation
Figures 3 and 4 show the T4 and M1 categories
within types of database submissions (Figure 3) and by
geographic region (Figure 4) for clinically staged cases.
We focused on the clinically assigned staging when we
compared these groups, because surgery was rarely per-
formed on these patients.
Although the majority of cases in the pleural dissemi-
nation group are from Europe and North America (primarily
from clinical trials and registries), the prognosis of this
category is consistently worse than other T4M0 cases and is
consistently better than cases with distant metastases, across
all regions and database types.
TABLE 3. Overall Survival Comparisons for Proposed Clinical Stage T4 (any N) versus Proposed Categories M1a (Pleural





Rate (%) Comparison HR p
T4 M0, any N 399 53 15
Pleural dissemination 488 36 2 vs. T4 1.70 0.0001
Contralateral lung nodules 362 45 3 vs. pleural dissemination 0.85 0.0235
M1 distant 4343 22 1 vs. contralateral lung nodules 1.61 0.0001
M1 distant vs. pleural dissemination 1.37 0.0001
TABLE 4. Overall Survival Comparisons for Proposed Best Stage T4 (any N) versus Proposed Categories M1a (Pleural





Rate (%) Comparison HR p
T4 M0, any N 1106 53 16
Pleural dissemination 771 45 6 vs. T4 1.91 0.0001
Contralateral lung nodules 369 46 3 vs. pleural dissemination 1.06 0.3816
M1 distant 4350 22 1 vs. contralateral lung nodules 1.56 0.0001
M1 distant vs. pleural dissemination 1.65 0.0001
TABLE 5. Comparison of Tumors with Nodule(s) in the Same Lobe, in the Same Lung, in the Opposite (Contralateral) Lung,





Rate (%) Comparison HR p
Same-lobe nodule(s)a 377 69 28
T4 (extension), any N 906 51 15 T4 extension vs. same lobe 1.61 0.0001
Same-side nodule(s) 200 61 21 Same side vs. T4 extension 0.75 0.0010
Contralateral lung nodules 369 46 3 Contralateral lung vs. same side 1.90 0.0001
a The same-lobe nodule group consists of 377 cases, 375 of which were surgically managed. These cases were not included in the main analyses and are covered in more detail
in a separate paper.4
Journal of Thoracic Oncology • Volume 2, Number 8, August 2007 Proposals for Revision of M Descriptors
Copyright © 2007 by the International Association for the Study of Lung Cancer 689
Median survival across regions and database types for
cases with metastases limited to the lung ranged from 9 to 11
months. For cases with distant metastases, median survival is
from 4 to 7 months across regions and database types. The
internal validation process supports the recommendations to
move the cases with pleural dissemination to the M1 and to
subdivide the M1 into M1a (lung and pleura) and M1b
(distant metastases).
External Validation
The North American Surveillance, Epidemiology and
End Results Registries population for external validation of
M recommendations included 27,393 patients staged T4 (as
previously described) or M1; overall survival for these cases
is shown in Figure 5. Survival is generally poorer than in the
IASLC database, but the ordering of categories supports the
recommendations. Median survival for cases with pleural
dissemination is 4 months, and the 1-year survival rate is 21%
versus 10 months for other T4 cases (1-year survival rate,
40%). Cases with one or more nodules in the contralateral
lung have a median survival of 6 months (1-year survival
rate, 31%), and cases with extrathoracic metastases have a
median survival of 3 months (1-year survival rate, 15%).
DISCUSSION
Accurate staging is essential for patient management,
particularly when designating the M descriptor. Roughly
speaking, this means initiating a therapy with a chance of
FIGURE 3. Comparisons of clinical
T4/M1 within database types.
FIGURE 4. Comparisons of clinical
T4/M1 within region.
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long-term survival or cure, rather than palliative therapy,
including chemotherapy.
The currently used staging system is based on a rela-
tively small database without validation for individual T, N,
and M descriptors in previous iterations. In addition, this
database recruited from a limited geographic area and is
composed predominantly of surgical cases.
The current analysis was performed to help redefine
the current classification system on the basis of a large
number of lung cancer cases from around the world. The
database has extensive patient information, although no
uniform staging protocol was available. The majority of
patients were clinically staged with conventional imaging
that included computed tomography of the chest and upper
abdomen. Overall, the staging procedures were consistent
for a relatively short period of 10 years. Additional studies
were not systematically obtained if there was no clinical
suspicion of metastases; examples of these are bone scin-
tigraphy and brain computed tomography or magnetic
resonance imaging.7 We recognize that this nonuniform
collection of imaging studies and pathological proof is a
limitation of any large, multinational database.8
The results from this analysis are obtained from the
largest lung cancer database ever accumulated and currently
provide the best possible evidence to support changes in the
TNM system. For instance, the M group within the database
is four times larger than the one used for the previous
revision. Now, for the first time, it is possible to properly
evaluate the classification of additional pulmonary nodules
introduced in the 1997 edition of the TNM classification for
lung cancer. The specific recommendations focus on changes
in the T4 and M categories. The recommendations as de-
scribed above will reclassify malignant pleural disease from
T4 to M1a. Regarding the M factor, better outcomes for
patients with contralateral nodule(s) now grouped as M1a
were found compared with distant extrathoracic metastases
now designated as M1b.
It is unclear why there is a prognostic difference be-
tween distant metastases in the other lung (new M1a) versus
other sites (new M1b). Unfortunately, from the database it is
not possible to differentiate between cases with multiple
lesions in the contralateral lung or a single nodule. For single
M1 lesions in the lung, there is always a question of whether
this is M1 disease or multiple primaries.9,10,1112–15 Without
comparing a tissue sample of both lesions, the question
usually remains unanswered, and even if identical histology
is found, this does not exclude two primaries.16,17 Often, it is
impossible to get tissue from the primary and possible me-
tastases or second primary by means other than a thoracot-
omy. Therefore, a clinical decision is often made after eval-
uating other criteria such as radiological characteristics.12 A
spiculated or lobulated lesion often indicates a primary tu-
mor, whereas a smooth border is more often seen in hemato-
geneic metastases. Potentially, a number of cases in the
database might be operated as second primaries, thus improv-
ing the overall prognosis of the new M1a group. With this in
mind, a clinician treating a patient with a single contralateral
lung lesion still must decide whether this patient is a candi-
date for a “benefit of doubt” approach and should not be
treated as disseminated disease (stage IV) by systemic treat-
ment but as two primaries, which might both be candidates
for treatment with curative intent. For these situations, new
and promising treatments such as 4D high-dose radiotherapy
might be indicated.18,19
This analysis has raised additional questions that cannot
be addressed by the current database. A prospective collec-
tion of patient data will be essential for future TMN revisions.
This will provide guidelines as to what information should be
considered as minimal staging procedures and what, ideally,
should be performed.20,21
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